

July 20, 2026

PRIOR AUTHORIZATION FOR HIGH-COST CLINICIAN ADMINISTERED DRUG (HCCAD) OMISIRGE EFFECTIVE JULY 1, 2026

BACKGROUND

HHSC will add Omisirge (Omidubicel-only) (procedure code J3590) as a Medicaid and CHIP benefit beginning on July 1, 2026. Community Health Choice requires prior authorization for this medication effective immediately.

KEY DETAILS

Omisirge (omidubicel-only) is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from cord blood indicated for the following:

- a. Hematologic malignancies in patients aged 12 years and older who are planned for umbilical cord blood transplantation (UCBT) following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
- b. Severe aplastic anemia (SAA) in patients aged 6 years of age and older following reduced intensity conditioning.

HHSC will reimburse Omisirge as non-risk and designate it as a high-cost clinician-administered drug (HCCAD). The HHSC-approved clinical prior authorization is mandatory for MCOs.

ACTION

HHSC approved this updated clinical prior authorization for use by MCOs. HHSC will implement the Fee For Service criteria on Sept. 1, 2026.

ADDITIONAL INFORMATION

Refer to the [Outpatient Drug Services Handbook Chapter](#) of the Texas Medicaid Provider Procedure Manual for the current HCCADs list and for more details on the clinical policy and prior authorization requirements. HHSC will publish the Omisirge maximum allowable rate on the [Static Fee Schedule](#). Users should scroll down the page to the National Drug Codes section for more information.

RESOURCES

Attachment:	2026.0629 - omisirge criteria.pdf
--------------------	---

QUESTIONS

For any questions regarding this notice, please contact your Community Provider Performance Manager (provider representative). E-mail: ProviderRelationsInquiries@CommunityHealthChoice.org